These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 7536072

  • 21. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M, Couture F, Kovacs M, Saragosa R, McCrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L, Keating A.
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [Abstract] [Full Text] [Related]

  • 22. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC.
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [Abstract] [Full Text] [Related]

  • 23. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG, Crown JP, Wasserheit C, Kritz A, Wong G, Reich L, Norton L, Moore MA.
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [Abstract] [Full Text] [Related]

  • 24. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
    Jansen J, Thompson EM, Hanks S, Greenspan AR, Thompson JM, Dugan MJ, Akard LP.
    Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
    [Abstract] [Full Text] [Related]

  • 25. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS, Leather HL, Nejame C, Meyer C, Wingard JR.
    Cytotherapy; 2002 Jun; 4(6):531-8. PubMed ID: 12568989
    [Abstract] [Full Text] [Related]

  • 26. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
    Dahl E, Burroughs J, DeFor T, Verfaillie C, Weisdorf D.
    Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
    [Abstract] [Full Text] [Related]

  • 27. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L, Tischler HJ, Battmer K, Südmeier I, Casper J, Link H.
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [Abstract] [Full Text] [Related]

  • 28. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
    Zimmerman TM, Mick R, Myers S, Bender JG, Lee WJ, Williams SF.
    Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
    [Abstract] [Full Text] [Related]

  • 29. High dose therapy and autologous bone marrow versus blood cell rescue. South Island Bone Marrow Transplant Unit.
    Hill GR, Inder A, Patton WN, Hart DN.
    N Z Med J; 1996 Feb 23; 109(1016):45-8. PubMed ID: 8598936
    [Abstract] [Full Text] [Related]

  • 30. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor.
    Kohno A, Takeyama K, Narabayashi M, Okamoto R, Adachi I, Tobinai K, Shimoyama M.
    Bone Marrow Transplant; 1995 Jan 23; 15(1):49-54. PubMed ID: 7538002
    [Abstract] [Full Text] [Related]

  • 31. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
    Faucher C, Le Corroller AG, Chabannon C, Novakovitch G, Manonni P, Moatti JP, Nouyrigat P, Maraninchi D, Blaise D.
    Bone Marrow Transplant; 1996 Apr 23; 17(4):533-6. PubMed ID: 8722350
    [Abstract] [Full Text] [Related]

  • 32. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec 23; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 33. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
    Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, Nauta JJ, van der Hem KG, Dräger AM, Langenhuijsen MM.
    Bone Marrow Transplant; 1994 Jan 23; 13(1):37-41. PubMed ID: 7517255
    [Abstract] [Full Text] [Related]

  • 34. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S, Goldschmidt H, Ehrhardt R, Haas R.
    Exp Hematol; 1993 Apr 23; 21(4):508-14. PubMed ID: 7681782
    [Abstract] [Full Text] [Related]

  • 35. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH, Christiansen NP, Fay JP, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP.
    Exp Hematol; 1996 Oct 23; 24(12):1363-8. PubMed ID: 8913281
    [Abstract] [Full Text] [Related]

  • 36. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I, Prosper BF, Marugan I, Lluch A, Arbona C, Castillo I, Solano C, Garcia-Conde J.
    Bone Marrow Transplant; 1999 Jun 23; 23(11):1101-7. PubMed ID: 10382948
    [Abstract] [Full Text] [Related]

  • 37. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
    Andrews RG, Briddell RA, Hill R, Gough M, McNiece IK.
    Stem Cells; 1999 Jun 23; 17(4):210-8. PubMed ID: 10437984
    [Abstract] [Full Text] [Related]

  • 38. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J.
    Bone Marrow Transplant; 1995 Nov 23; 16(5):655-61. PubMed ID: 8547862
    [Abstract] [Full Text] [Related]

  • 39. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H, Wake A, Yamasaki Y, Izumi Y.
    Rinsho Ketsueki; 2000 Jun 23; 41(6):500-6. PubMed ID: 10921350
    [Abstract] [Full Text] [Related]

  • 40. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P.
    Haematologica; 1998 Apr 23; 83(4):329-37. PubMed ID: 9592983
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.